Affordable Access

Phase II study of 4'-deoxydoxorubicin in advanced colorectal cancer.

Authors
  • Falkson, G
  • Vorobiof, D A
Type
Published Article
Journal
Investigational new drugs
Publication Date
Jan 01, 1986
Volume
4
Issue
2
Pages
165–169
Identifiers
PMID: 3733376
Source
Medline
License
Unknown

Abstract

Thirty-three patients with advanced colorectal cancer were entered on a phase II study of 4'-deoxydoxorubicin (esorubicin) (30-35 mg/m2 q 3 weekly). Objective response was documented in 4 of 25 previously untreated patients and in none of 8 previously treated patients. Toxicity was acceptable with grade 3 or 4 leukopenia occurring in 8 patients. Complete alopecia occurred only in 4 patients and gastro-intestinal toxicity was mild. A significant decrease (greater than 10%) of the left ventricular ejection fraction occurred in 8/23 patients who received greater than 2 courses of treatment.

Report this publication

Statistics

Seen <100 times